ADAP

Adaptimmune Therapeutics PLC

This asset is no longer available for investment.

View all assets

Price

return (12m)

p/e

-0.10

p/bv

-0.24

DIVIDEND YIELD

0.00%

ADAP price

Adaptimmune Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment ADAP

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals ADAP

Valuation

P/E

-0.10

Sector -3.50

Industry -3.50

P/BV

-0.24

Sector 2.01

Industry 2.01

P/Revenue (PSR)

0.26

Sector 2.01

Industry 2.01

EV/EBITDA

-0.64

Sector -223.67

Industry -223.67

EV/EBIT

-0.58

Sector -47.92

Industry -47.92

P/EBITDA

-0.11

Sector -21.50

Industry -21.50

P/EBIT

-0.11

Sector -28.21

Industry -28.21

P/Total Assets

0.13

Sector 1.19

Industry 1.19

P/Net Current Assets

-0.14

Sector -10.26

Industry -10.26

P/Working Capital

0.64

Sector -167.98

Industry -167.98

EPS

-0.64

Sector -1.79

Industry -1.79

BVPS

-0.27

Sector 2.06

Industry 2.06

Efficiency

Gross Margin

94.81%

Sector 41.30%

Industry 41.30%

EBITDA Margin

-191.96%

Sector -17,117.21%

Industry -17,117.21%

EBIT Margin

-210.31%

Sector -4,185,659.35%

Industry -4,185,659.35%

Operating Margin

-100.00%

Sector -35.21%

Industry -35.21%

Net Profit Margins

-100.00%

Sector -35.91%

Industry -35.91%

Asset Turnover

0.10

Sector 0.02

Industry 0.02

Profitability

ROE

239.23%

Sector -56.67%

Industry -56.67%

ROA

-129.95%

Sector -59.91%

Industry -59.91%

ROIC

-148.03%

Sector -2,335.95%

Industry -2,335.95%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

1.52

Sector 2.89

Industry 2.89

Net Debt / EBITDA

0.01

Sector -14,066,680.10

Industry -14,066,680.10

Net Debt / EBIT

0.01

Sector -8.06

Industry -8.06

Net Debt / Equity

0.01

Sector -33,024.69

Industry -33,024.69

Gross Debt / Equity

-0.36

Sector -0.85

Industry -0.85

Equity/Assets

-0.54

Sector 0.46

Industry 0.46

Liabilities/Assets

1.54

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

60.30%

Sector -

Industry -

5Y Earnings CAGR

1.43%

Sector -

Industry -

Fundamentals ADAP

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
ADAP Adaptimmune Therapeutics PLC	$0.00	-100.00%	0.00%	-0.10	-0.24	239.23%	-100.00%
JNJ Johnson & Johnson	$269.99	56.71%	1.96%	30.82	7.63	24.76%	21.48%
PFE Pfizer Inc.	$27.66	23.21%	6.26%	35.85	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$263.96	22.44%	2.59%	73.99	-78.76	-106.44%	9.81%
NVO Novo Nordisk A/S	$43.24	-26.07%	4.29%	10.56	5.61	53.11%	35.32%
MRK Merck & Co. Inc.	$146.87	87.26%	2.31%	113.21	8.55	7.55%	4.76%
AZN AstraZeneca PLC	$166.08	10.74%	1.94%	19.88	5.12	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$63.06	48.20%	4.04%	13.67	5.68	41.55%	18.85%
ZTS Zoetis Inc.	$71.40	-50.11%	2.88%	11.47	9.64	84.02%	27.77%
AMGN Amgen Inc.	$385.65	38.85%	2.60%	23.66	17.70	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$784.85	33.10%	0.47%	18.63	2.54	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$112.45	44.52%	0.00%	31.57	90.97	288.13%	24.86%
MCK McKesson Corporation	$874.65	25.89%	0.38%	19.57	-26.84	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$508.34	32.68%	0.00%	29.15	6.34	21.76%	35.00%
CAH Cardinal Health Inc.	$225.38	52.58%	0.91%	30.53	-19.32	-63.29%	0.68%
ARGX argenx SE	$990.32	34.42%	0.00%	2.24	2.63	117.11%	44.68%
HRMY Harmony Biosciences Holdings Inc.	$42.02	29.13%	0.00%	13.50	2.45	18.14%	18.88%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

ADAP Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Adaptimmune Therapeutics

Adaptimmune Therapeutics PLC

Average Investor10 user rating

4.0 (2 people)

United States

12 years

Founded: 2014

2015

Time since IPO - 11 years

400

Employees

Adaptimmune Therapeutics PLC (United States) is listed on the Nasdaq and has a market capitalization of $17.08 million, with shareholders equity totaling $-70.96 million.

The company employs approximately 400 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Adaptimmune Therapeutics PLC reported $65.09 million in revenue, generating net income of $-169.76 million.

Key financial metrics include a P/E ratio of -0.10, a price-to-book (P/B) ratio of -0.24, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker ADAP.

Market cap

$17.08 million

Net worth

$-70.96 million

$-70,960,000.00

Assets

$130.63 million

$130,630,000.00

Total Shares Outstanding

264.00 million

264,000,000

Average Daily Trading Volume

$112.66 million

$112,660,029.28

Sector

Health Care

Industry

Biotechnology

ADAP

ADAP revenue and profits

Financial Results ADAP

DRAG THE FRAME TO SEE MORE DATA

ADAP cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$874.65 25,89% (12M)

P/E

19.57

0.38%

ROE

-137.16%

P/BV

-26.84

CAH - Cardinal Health

$225.38 52,58% (12M)

P/E

30.53

0.91%

ROE

-63.29%

P/BV

-19.32

JNJ - Johnson & Johnson

$269.99 56,71% (12M)

P/E

30.82

1.96%

ROE

24.76%

P/BV

7.63

ABBV - AbbVie

$263.96 22,44% (12M)

P/E

73.99

2.59%

ROE

-106.44%

P/BV

-78.76

MRK - Merck & Co.

$146.87 87,26% (12M)

P/E

113.21

2.31%

ROE

7.55%

P/BV

8.55

AZN - AstraZeneca

$166.08 9,00% (12M)

P/E

19.88

1.94%

ROE

25.77%

P/BV

5.12

PFE - Pfizer

$27.66 23,21% (12M)

P/E

35.85

6.26%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$874.65 25,89% (12 M)

P/L

19.57

0.38%

ROE

-137.16%

P/VP

-26.84

CAH - Cardinal Health

$225.38 52,58% (12 M)

P/L

30.53

0.91%

ROE

-63.29%

P/VP

-19.32

JNJ - Johnson & Johnson

$269.99 56,71% (12 M)

P/L

30.82

1.96%

ROE

24.76%

P/VP

7.63

ABBV - AbbVie

$263.96 22,44% (12 M)

P/L

73.99

2.59%

ROE

-106.44%

P/VP

-78.76

MRK - Merck & Co.

$146.87 87,26% (12 M)

P/L

113.21

2.31%

ROE

7.55%

P/VP

8.55

AZN - AstraZeneca

$166.08 9,00% (12 M)

P/L

19.88

1.94%

ROE

25.77%

P/VP

5.12

PFE - Pfizer

$27.66 23,21% (12 M)

P/L

35.85

6.26%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of Adaptimmune Therapeutics (ADAP) today?

A cotação de Adaptimmune Therapeutics (ADAP) hoje está em US$ 0.00, com uma variação de 0% em relação ao último ano. A cotação de Adaptimmune Therapeutics (ADAP) iniciou o ano negociando na casa dos US$ 0.00 e hoje está em US$ 0.00. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Adaptimmune Therapeutics (ADAP) e dados de ações do Ibovespa e mercados internacionais.

Quando Adaptimmune Therapeutics (ADAP) paga dividendos?

Adaptimmune Therapeutics (ADAP) não distribuiu dividendos no último ano.

Is Adaptimmune Therapeutics (ADAP) a good investment?

Atualmente, Adaptimmune Therapeutics (ADAP) está cotada a US$ 0.00, com um P/L de -0.10, representando um desvio de -128% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 0 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Adaptimmune Therapeutics (ADAP) stock?

Investir em ações de Adaptimmune Therapeutics (ADAP) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Adaptimmune Therapeutics (ADAP) yield today?

A rentabilidade de Adaptimmune Therapeutics (ADAP) foi de 0.00% no último mês, 0.00% no último ano e 0.00% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Adaptimmune Therapeutics (ADAP) hoje, o investimento total seria de US$ 0.00, com base na cotação atual de US$ 0.00.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 0.00
Em 5 anos: US$ 0.00
Em 10 anos: US$ 0.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

ADAP

Adaptimmune Therapeutics PLC

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment ADAP

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING ADAP WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Adaptimmune Therapeutics

Adaptimmune Therapeutics PLC

United States

12 years

2015

400

PROFIT X PRICE ADAP

Financial Results ADAP

ADAP cash flow

Asset, Revenue and Profit Growth - ADAP

ADAP balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions